Shares of Verastem Inc (NASDAQ:VSTM) were down 5.6% during trading on Tuesday . The company traded as low as $2.83 and last traded at $2.84. Approximately 2,628,618 shares were traded during trading, a decline of 4% from the average daily volume of 2,728,496 shares. The stock had previously closed at $3.01.

VSTM has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Verastem from a “hold” rating to a “strong-buy” rating and set a $4.00 target price on the stock in a report on Saturday, January 19th. HC Wainwright decreased their price target on shares of Verastem from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, March 14th. BidaskClub downgraded shares of Verastem from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 16th. Finally, Cantor Fitzgerald initiated coverage on shares of Verastem in a research report on Wednesday, April 3rd. They issued an “overweight” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Verastem currently has a consensus rating of “Buy” and a consensus target price of $11.64.

The firm has a market capitalization of $222.50 million, a PE ratio of -2.07 and a beta of 3.03. The company has a quick ratio of 6.82, a current ratio of 6.83 and a debt-to-equity ratio of 0.92.

Verastem (NASDAQ:VSTM) last released its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.23. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $5.56 million. Research analysts forecast that Verastem Inc will post -1.84 earnings per share for the current fiscal year.

In other Verastem news, Director Timothy J. Barberich purchased 33,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $3.21 per share, with a total value of $105,930.00. Following the purchase, the director now owns 168,000 shares in the company, valued at $539,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of VSTM. Principal Financial Group Inc. purchased a new stake in shares of Verastem during the 4th quarter valued at about $35,000. Amalgamated Bank acquired a new stake in Verastem during the 4th quarter valued at $35,000. MML Investors Services LLC grew its holdings in Verastem by 70.0% during the 4th quarter. MML Investors Services LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 7,000 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Verastem during the 4th quarter worth $62,000. Finally, Blueshift Asset Management LLC purchased a new stake in Verastem during the 4th quarter worth $62,000. 59.15% of the stock is owned by institutional investors.

WARNING: “Verastem (VSTM) Stock Price Down 5.6%” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/verastem-vstm-stock-price-down-5-6/2951453.html.

About Verastem (NASDAQ:VSTM)

Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Further Reading: Growth and Income Funds

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.